Literature DB >> 20105011

Per aspirin ad astra...

Thomas Hartung1.   

Abstract

Taking the 110th anniversary of marketing of aspirin as starting point, the almost scary toxicological profile of aspirin is contrasted with its actual use experience. The author concludes that we are lucky that, in 1899, there was no regulatory toxicology. Adding, for the purpose of this article, a fourth R to the Three Rs, i.e. Realism, three reality-checks are carried out. The first one comes to the conclusion that the tools of toxicology are hardly adequate for the challenges ahead. The second one concludes that, specifically, the implementation of the EU REACH system is not feasible with these tools, mainly with regard to throughput. The third one challenges the belief that classical alternative methods, i.e. replacing animal test-based tools one by one, is actually leading to a new toxicology - it appears to change only patches of the patchwork, but not to overcome any inherent limitations other than ethical ones. The perspective lies in the Toxicology for the 21st Century initiatives, which aim to create a new approach from the scratch, by an evidence-based toxicology and a global "Human Toxicology Programme". 2009 FRAME.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20105011     DOI: 10.1177/026119290903702S10

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  5 in total

Review 1.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

2.  Look back in anger - what clinical studies tell us about preclinical work.

Authors:  Thomas Hartung
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

3.  Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.

Authors:  Catherine Willett; Jessica Caverly Rae; Katy O Goyak; Gary Minsavage; Carl Westmoreland; Melvin Andersen; Mark Avigan; Daniel Duché; Georgina Harris; Thomas Hartung; Hartmut Jaeschke; Andre Kleensang; Brigitte Landesmann; Suzanne Martos; Marilyn Matevia; Colleen Toole; Andrew Rowan; Terry Schultz; Jennifer Seed; John Senior; Imran Shah; Kalyanasundaram Subramanian; Mathieu Vinken; Paul Watkins
Journal:  ALTEX       Date:  2014-01-28       Impact factor: 6.043

4.  The flaws and human harms of animal experimentation.

Authors:  Aysha Akhtar
Journal:  Camb Q Healthc Ethics       Date:  2015-10       Impact factor: 1.284

Review 5.  The ascendance of microphysiological systems to solve the drug testing dilemma.

Authors:  Eva-Maria Dehne; Tobias Hasenberg; Uwe Marx
Journal:  Future Sci OA       Date:  2017-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.